BiotechTube

KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BID

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Surgical Ocular Inflammation and Pain

Conditions

Post Surgical Ocular Inflammation and Pain

Trial Timeline

Jun 1, 2016 → Mar 1, 2017

NCT ID
NCT02793817

About KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BID

KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BID is a phase 3 stage product being developed by Kala Pharmaceuticals for Post Surgical Ocular Inflammation and Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02793817. Target conditions include Post Surgical Ocular Inflammation and Pain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02793817Phase 3Completed

Competing Products

20 competing products in Post Surgical Ocular Inflammation and Pain

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
PRF110PainReformPhase 2
44
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
Placebo + DS-5565Daiichi SankyoPre-clinical
23
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
77
QUTENZAAstellas PharmaApproved
85
QutenzaAstellas PharmaPre-clinical
23
CelecoxibAstellas PharmaPre-clinical
23
ASP8477 + PlaceboAstellas PharmaPhase 2
52

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% + Prednisolone acetatePhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69
KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%Phase 3
69